SEC Form 4 · accession 0000905148-16-001627
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Shannon
Director
Period of report
May 19, 2016
Accepted (ET)
May 23, 2016 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F1 | May 19, 2016 | S | 2,500 | $10.14 | D | 4,582,255 | I | See Footnote |
| Common StockF3,F1 | May 20, 2016 | S | 6,187 | $10.09 | D | 4,576,068 | I | See Footnote |
| Common StockF4 | holding | — | — | — | 134 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares of Common Stock ("Shares") are held directly by Canaan IX L.P. The Reporting Person is a non-managing member of Canaan Partners IX LLC, the general partner of Canaan IX L.P. The Reporting Person does not have voting, investment or dispositive power over any of the Shares directly held by Canaan IX L.P. and disclaims beneficial ownership of the Shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
- F2The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $10.00 - $10.25, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 - $10.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
- F4These shares of Common Stock were previously reported by the Reporting Person as indirectly beneficially owned. These shares became directly beneficially owned by the Reporting Person following pro rata distributions of shares on April 25, 2016 by Canaan IX L.P. and Canaan Partners IX LLC, which were exempt from Section 16 of the Exchange Act under Rule 16a-13.
Remarks
Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on October 7, 2015)